Sagimet Biosciences Inc. Series A Common Stock SGMT
Analyst Ratings
- Consensus
- Buy — 5 Buy · 1 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $29.33 (+178.0% upside)
Key Stats
- Today's Range
- $9.07 – $10.60
- 50-Day Range
- $6.24 – $10.60
- 52-Week Range
- $4.50 – $11.41
- Volume
- 2.66 million shs
- Average Volume
- 1.16 million shs
- Market Cap
- $655.77 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.89%
- Days to Cover
- 2.93
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Related Stocks
Compare head-to-head: SGMT vs LLY·SGMT vs JNJ·SGMT vs ABBV·SGMT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.